Cargando…

A Mixture of U.S. Food and Drug Administration–Approved Monoaminergic Drugs Protects the Retina From Light Damage in Diverse Models of Night Blindness

PURPOSE: The purpose of this study was to test the extent of light damage in different models of night blindness and apply these paradigms in testing the therapeutic efficacy of combination therapy by drugs acting on the G(i), G(s), and G(q) protein-coupled receptors. METHODS: Acute bright light exp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leinonen, Henri, Choi, Elliot H., Gardella, Anthony, Kefalov, Vladimir J., Palczewski, Krzysztof
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Association for Research in Vision and Ophthalmology 2019
Materias:	Physiology and Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736410/ https://www.ncbi.nlm.nih.gov/pubmed/30947334 http://dx.doi.org/10.1167/iovs.19-26560

Ejemplares similares

Homeostatic plasticity in the retina is associated with maintenance of night vision during retinal degenerative disease
por: Leinonen, Henri, et al.
Publicado: (2020)

Drugs and Devices: Comparison of European and U.S. Approval Processes
por: Van Norman, Gail A.
Publicado: (2016)

Monoaminergic Mechanisms in Epilepsy May Offer Innovative Therapeutic Opportunity for Monoaminergic Multi-Target Drugs
por: Svob Strac, Dubravka, et al.
Publicado: (2016)

Financing of U.S. Biomedical Research and New Drug Approvals across Therapeutic Areas
por: Dorsey, E. Ray, et al.
Publicado: (2009)

U.S. Food and Drug Administration: Review for the Emergency Physician of Approval Process and Limitations
por: Zuabi, Nadia, et al.
Publicado: (2016)

Stress resilience-enhancing drugs preserve tissue structure and function in degenerating retina via phosphodiesterase inhibition
por: C. Luu, Jennings, et al.
Publicado: (2023)

Older U.S. Adults With Nocturia Often Cannot Use the Only FDA-Approved Drugs for the Condition
por: Johnson, Theodore, et al.
Publicado: (2020)

Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration
por: Jiao, Kuo, et al.
Publicado: (2019)

Use of Extrapolation in New Drug Approvals by the US Food and Drug Administration
por: Feldman, Daniel, et al.
Publicado: (2022)

Retinoids in the visual cycle: role of the retinal G protein-coupled receptor
por: Choi, Elliot H., et al.
Publicado: (2021)

Participation of the elderly, women, and minorities in pivotal trials supporting 2011–2013 U.S. Food and Drug Administration approvals
por: Downing, Nicholas S., et al.
Publicado: (2016)

Review of Evidence Supporting 2022 US Food and Drug Administration Drug Approvals
por: Kaplan, Robert M., et al.
Publicado: (2023)

2095 Drug screening and hit identification for night blindness with zebrafish
por: Ganzen, Logan, et al.
Publicado: (2018)

Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals
por: Lammers, Austin, et al.
Publicado: (2017)

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020
por: Kayki-Mutlu, Gizem, et al.
Publicado: (2021)

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
por: Kayki-Mutlu, Gizem, et al.
Publicado: (2022)

Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020
por: Mitra-Majumdar, Mayookha, et al.
Publicado: (2022)

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022
por: Kayki-Mutlu, Gizem, et al.
Publicado: (2023)

Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval
por: Parikh, Ravi B., et al.
Publicado: (2023)

Monoaminergic Neuromodulation of Sensory Processing
por: Jacob, Simon N., et al.
Publicado: (2018)

Impressive Words: Linguistic Predictors of Public Approval of the U.S. Congress
por: Decter-Frain, Ari, et al.
Publicado: (2016)

Clinical development time is shorter for new anticancer drugs approved via accelerated approval in the US or via conditional approval in the EU
por: Demirci, Ebru, et al.
Publicado: (2023)

Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021
por: Gupta, Ravi, et al.
Publicado: (2022)

Conditional deletion of Des1 in the mouse retina does not impair the visual cycle in cones
por: Kiser, Philip D., et al.
Publicado: (2019)

Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020
por: Miljković, Miloš D., et al.
Publicado: (2022)

Public opinion regarding U.S. Food and Drug Administration approval of aducanumab and potential policy responses: A nationally representative survey
por: DiStefano, Michael J., et al.
Publicado: (2022)

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
por: Cherla, Avi, et al.
Publicado: (2021)

Recent Trends in Medicaid Spending and Use of Drugs With US Food and Drug Administration Accelerated Approval
por: Sachs, Rachel E., et al.
Publicado: (2021)

Correction to: A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
por: Kayki-Mutlu, Gizem, et al.
Publicado: (2022)

Time for the US food and drug administration approval of condoms for anal intercourse
por: Nguyen, Brian T., et al.
Publicado: (2019)

Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000–2020)
por: Kim, Jeeyun A., et al.
Publicado: (2021)

Night-Blindness
por: Hailes, Clements
Publicado: (1899)

Night Blindness
Publicado: (1876)

Night Blindness
por: Dass, Bhowani
Publicado: (1876)

Night-Blindness
por: Smith, Henry
Publicado: (1905)

Night-Blindness
por: Husain, Basharat
Publicado: (1905)

Requirements and Study Designs for U.S. Regulatory Approval of Influenza Home Tests
por: Yang, Tony, et al.
Publicado: (2022)

The Dynamics of Somatic Exocytosis in Monoaminergic Neurons
por: Sarkar, Bidyut, et al.
Publicado: (2012)

Monoaminergic Modulation of Motor Cortex Function
por: Vitrac, Clément, et al.
Publicado: (2017)

The monoaminergic system is a bilaterian innovation
por: Goulty, Matthew, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tbad4q8oi4pobpvndb11d16a6h